Cargando…
Hypercoagulopathy and Adipose Tissue Exacerbated Inflammation May Explain Higher Mortality in COVID-19 Patients With Obesity
COVID-19, caused by SARS-CoV-2, is characterized by pneumonia, lymphopenia, exhausted lymphocytes and a cytokine storm. Several reports from around the world have identified obesity and severe obesity as one of the strongest risk factors for COVID-19 hospitalization and mechanical ventilation. Moreo...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7399077/ https://www.ncbi.nlm.nih.gov/pubmed/32849309 http://dx.doi.org/10.3389/fendo.2020.00530 |
_version_ | 1783566078511677440 |
---|---|
author | Pasquarelli-do-Nascimento, Gabriel Braz-de-Melo, Heloísa Antoniella Faria, Sara Socorro Santos, Igor de Oliveira Kobinger, Gary P. Magalhães, Kelly Grace |
author_facet | Pasquarelli-do-Nascimento, Gabriel Braz-de-Melo, Heloísa Antoniella Faria, Sara Socorro Santos, Igor de Oliveira Kobinger, Gary P. Magalhães, Kelly Grace |
author_sort | Pasquarelli-do-Nascimento, Gabriel |
collection | PubMed |
description | COVID-19, caused by SARS-CoV-2, is characterized by pneumonia, lymphopenia, exhausted lymphocytes and a cytokine storm. Several reports from around the world have identified obesity and severe obesity as one of the strongest risk factors for COVID-19 hospitalization and mechanical ventilation. Moreover, countries with greater obesity prevalence have a higher morbidity and mortality risk of developing serious outcomes from COVID-19. The understanding of how this increased susceptibility of the people with obesity to develop severe forms of the SARS-CoV-2 infection occurs is crucial for implementing appropriate public health and therapeutic strategies to avoid COVID-19 severe symptoms and complications in people living with obesity. We hypothesize here that increased ACE2 expression in adipose tissue displayed by people with obesity may increase SARS-CoV-2 infection and accessibility to this tissue. Individuals with obesity have increased white adipose tissue, which may act as a reservoir for a more extensive viral spread with increased shedding, immune activation and pro-inflammatory cytokine amplification. Here we discuss how obesity is related to a pro-inflammatory and metabolic dysregulation, increased SARS-CoV-2 host cell entry in adipose tissue and induction of hypercoagulopathy, leading people with obesity to develop severe forms of COVID-19 and also death. Taken together, it may be crucial to better explore the role of visceral adipose tissue in the inflammatory response to SARS-CoV-2 infection and investigate the potential therapeutic effect of using specific target anti-inflammatories (canakinumab or anakinra for IL-1β inhibition; anti-IL-6 antibodies for IL-6 inhibition), anticoagulant or anti-diabetic drugs in COVID-19 treatment of people with obesity. Defining the immunopathological changes in COVID-19 patients with obesity can provide prominent targets for drug discovery and clinical management improvement. |
format | Online Article Text |
id | pubmed-7399077 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-73990772020-08-25 Hypercoagulopathy and Adipose Tissue Exacerbated Inflammation May Explain Higher Mortality in COVID-19 Patients With Obesity Pasquarelli-do-Nascimento, Gabriel Braz-de-Melo, Heloísa Antoniella Faria, Sara Socorro Santos, Igor de Oliveira Kobinger, Gary P. Magalhães, Kelly Grace Front Endocrinol (Lausanne) Endocrinology COVID-19, caused by SARS-CoV-2, is characterized by pneumonia, lymphopenia, exhausted lymphocytes and a cytokine storm. Several reports from around the world have identified obesity and severe obesity as one of the strongest risk factors for COVID-19 hospitalization and mechanical ventilation. Moreover, countries with greater obesity prevalence have a higher morbidity and mortality risk of developing serious outcomes from COVID-19. The understanding of how this increased susceptibility of the people with obesity to develop severe forms of the SARS-CoV-2 infection occurs is crucial for implementing appropriate public health and therapeutic strategies to avoid COVID-19 severe symptoms and complications in people living with obesity. We hypothesize here that increased ACE2 expression in adipose tissue displayed by people with obesity may increase SARS-CoV-2 infection and accessibility to this tissue. Individuals with obesity have increased white adipose tissue, which may act as a reservoir for a more extensive viral spread with increased shedding, immune activation and pro-inflammatory cytokine amplification. Here we discuss how obesity is related to a pro-inflammatory and metabolic dysregulation, increased SARS-CoV-2 host cell entry in adipose tissue and induction of hypercoagulopathy, leading people with obesity to develop severe forms of COVID-19 and also death. Taken together, it may be crucial to better explore the role of visceral adipose tissue in the inflammatory response to SARS-CoV-2 infection and investigate the potential therapeutic effect of using specific target anti-inflammatories (canakinumab or anakinra for IL-1β inhibition; anti-IL-6 antibodies for IL-6 inhibition), anticoagulant or anti-diabetic drugs in COVID-19 treatment of people with obesity. Defining the immunopathological changes in COVID-19 patients with obesity can provide prominent targets for drug discovery and clinical management improvement. Frontiers Media S.A. 2020-07-28 /pmc/articles/PMC7399077/ /pubmed/32849309 http://dx.doi.org/10.3389/fendo.2020.00530 Text en Copyright © 2020 Pasquarelli-do-Nascimento, Braz-de-Melo, Faria, Santos, Kobinger and Magalhães. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Endocrinology Pasquarelli-do-Nascimento, Gabriel Braz-de-Melo, Heloísa Antoniella Faria, Sara Socorro Santos, Igor de Oliveira Kobinger, Gary P. Magalhães, Kelly Grace Hypercoagulopathy and Adipose Tissue Exacerbated Inflammation May Explain Higher Mortality in COVID-19 Patients With Obesity |
title | Hypercoagulopathy and Adipose Tissue Exacerbated Inflammation May Explain Higher Mortality in COVID-19 Patients With Obesity |
title_full | Hypercoagulopathy and Adipose Tissue Exacerbated Inflammation May Explain Higher Mortality in COVID-19 Patients With Obesity |
title_fullStr | Hypercoagulopathy and Adipose Tissue Exacerbated Inflammation May Explain Higher Mortality in COVID-19 Patients With Obesity |
title_full_unstemmed | Hypercoagulopathy and Adipose Tissue Exacerbated Inflammation May Explain Higher Mortality in COVID-19 Patients With Obesity |
title_short | Hypercoagulopathy and Adipose Tissue Exacerbated Inflammation May Explain Higher Mortality in COVID-19 Patients With Obesity |
title_sort | hypercoagulopathy and adipose tissue exacerbated inflammation may explain higher mortality in covid-19 patients with obesity |
topic | Endocrinology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7399077/ https://www.ncbi.nlm.nih.gov/pubmed/32849309 http://dx.doi.org/10.3389/fendo.2020.00530 |
work_keys_str_mv | AT pasquarellidonascimentogabriel hypercoagulopathyandadiposetissueexacerbatedinflammationmayexplainhighermortalityincovid19patientswithobesity AT brazdemeloheloisaantoniella hypercoagulopathyandadiposetissueexacerbatedinflammationmayexplainhighermortalityincovid19patientswithobesity AT fariasarasocorro hypercoagulopathyandadiposetissueexacerbatedinflammationmayexplainhighermortalityincovid19patientswithobesity AT santosigordeoliveira hypercoagulopathyandadiposetissueexacerbatedinflammationmayexplainhighermortalityincovid19patientswithobesity AT kobingergaryp hypercoagulopathyandadiposetissueexacerbatedinflammationmayexplainhighermortalityincovid19patientswithobesity AT magalhaeskellygrace hypercoagulopathyandadiposetissueexacerbatedinflammationmayexplainhighermortalityincovid19patientswithobesity |